Meet Jon, Muscle-Invasive Bladder Cancer (MIBC) Survivor and Signatera Patient

Jon was on a business trip to Stockholm when he noticed something was wrong. His urine had darkened — a symptom he initially brushed off, recalling a kidney stone he’d had years earlier. But his wife insisted he see his general practitioner as soon as he returned home.

At 66 years old, Jon received a diagnosis that changed everything: muscle-invasive bladder
cancer (MIBC). At the time, his prognosis was measured in months.

“They were preparing to take out my bladder,” Jon said.

Faced with a life-altering surgery, Jon chose a different path. He opted for a combination of
radiation and chemotherapy in hopes of preserving his bladder. Just two cycles into treatment, scans showed no evidence of disease in his bladder. A follow-up PET-CT confirmed there was no distant disease.

After completing his PET scan, Jon was introduced to Signatera on Valentine’s Day in 2024.
Less than a month later, on March 6, he received his first Signatera result — negative. He has
continued testing serially ever since.

“As far as I’m concerned, I’m less excited about getting my CT done every three months and
much more comfortable with Signatera,” Jon shared.

For Jon, Signatera has become a critical part of his survivorship plan — offering reassurance
during a time often filled with uncertainty.

“It is my beacon,” he said. “It is my one thing that tells me I’m doing okay.”

Today, Jon continues to move forward with confidence, knowing he has an additional layer of
surveillance watching closely for any signs of recurrence — and peace of mind guiding him
through survivorship.

“I’m one of the luckiest people I know,” Jon said. “It doesn’t get much better than this.”